[{"orgOrder":0,"company":"Vivus","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Phentermine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Mayo Clinic","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Mayo Clinic"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : QSIVA is a combination of phentermine, a sympathomimetic amine anorectic and topiramate extended-release, an antiepileptic drug. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adul...

                          Brand Name : Qsiva

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 17, 2023

                          Lead Product(s) : Phentermine,Topiramate

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase IV

                          Sponsor : Mayo Clinic

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank